scholarly journals OP0256 Hydroxychloroquine reduces risk of incident diabetes mellitus in primary sjÖgren syndrome patients: a propensity score matched population-based cohort study

Author(s):  
W.-S. Chen ◽  
C.-Y. Tsai ◽  
C.-C. chang
PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e5109 ◽  
Author(s):  
Tai-Chen Lin ◽  
Chien-Fang Tseng ◽  
Yu-Hsun Wang ◽  
Hui-Chieh Yu ◽  
Yu-Chao Chang

Many reports have mentioned the association between chronic periodontitis (CP) and primary Sjögren syndrome (pSS). However, no cohort study has been performed for the risk of pSS in patients with CP. In this study, we evaluated the risk of pSS from CP exposure in a nationwide population-based cohort study in Taiwan. We studied the claims data of Taiwanese population from 2001 to 2012. We identified 76,765 patients with CP from the National Health Insurance Database in Taiwan. We also selected 76,765 controls that were randomly frequency matched by age, sex, and index year from the general population. We analyzed the risk of pSS by using Cox proportional hazards regression models including sex, age, and comorbidities. In this study, 76,765 patients with CP (mean age: 40.8 years) and 76,765 controls (mean age: 41.0 years) were followed-up for 8.54 and 8.49 years, respectively. A total of 869 cases of pSS were identified in CP cohort and 483 cases in non-CP cohort. Multivariate Cox regression analysis indicated that the incidence rate of pSS was significantly higher in CP cohort than those who in non-CP cohort (adjusted HR: 1.79, 95% CI [1.60–2.00]). Taken together, this nationwide retrospective cohort study demonstrated that the risk of pSS was significantly higher in patients with CP than in the general population. The association between CP and pSS was significant in the female group.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Pei-I Kuo ◽  
Tzu-Min Lin ◽  
Yu-Sheng Chang ◽  
Tsung-Yun Hou ◽  
Hui-Ching Hsu ◽  
...  

AbstractThe risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in primary Sjogren syndrome (pSS) has rarely been explored. To explore the association between BRONJ and pSS, we conducted a population-based propensity-score-matched cohort study using Taiwan’s National Health Insurance Research Database, including pSS patients receiving antiosteoporotic therapy and patients without pSS receiving antiosteoporotic therapy. A 1:4 matched-pair cohort based on propensity score was created. The stratified Cox proportional hazards model compared the risk of BRONJ in the pSS and non-pSS groups. In the study, 23,280 pSS patients and 28,712,152 controls were enrolled. After matching, 348 patients with pSS receiving antiosteoporotic drugs and 50,145 without pSS receiving antiosteoporotic drugs were included for analysis. The risk of developing BRONJ was 1.96 times higher in pSS patients compared with non-pSS patients after adjustment for age, sex, and comorbidities. No dose–response effect was observed in the bisphosphonate-treated pSS cohorts, documented as the cumulative defined daily doses of either < 224 or ≥ 224 (hazard ratio [HR]: 2.407, 95% confidence interval [CI] 1.412–7.790; HR: 2.143, 95% CI 1.046–4.393, respectively) increased risk of developing osteonecrosis of the jaw. In conclusion, the risk of BRONJ is significantly higher in patients with pSS compared with the general population.


2018 ◽  
Vol 2018 (1) ◽  
Author(s):  
Lauren Paul ◽  
Rick Burnett ◽  
Jeffrey C. Kwong ◽  
Perry Hystad ◽  
Aaron van Donkelaar ◽  
...  

2020 ◽  
pp. jrheum.201352
Author(s):  
Yun-Tzu Liang ◽  
Pui-Ying Leong ◽  
James Cheng-Chung Wei

We have read with great interest in the article by Wang, et al on the higher incidence of non-Hodgkin lymphoma (NHL) in patients with primary Sjögren syndrome (pSS) and the higher incidence of pSS in patients with NHL1. Thank you for the discovery of the bilateral relationship between pSS and NHL in this nationwide population-based study1.


Oncotarget ◽  
2017 ◽  
Vol 8 (46) ◽  
pp. 80461-80471 ◽  
Author(s):  
Yao-Fan Fang ◽  
Yen-Fu Chen ◽  
Ting-Ting Chung ◽  
Lai-Chu See ◽  
Kuang-Hui Yu ◽  
...  

2017 ◽  
Vol 44 (8) ◽  
pp. 1184-1189 ◽  
Author(s):  
J. Antonio Aviña-Zubieta ◽  
Michael Jansz ◽  
Eric C. Sayre ◽  
Hyon K. Choi

Objective.To estimate the future risk and time trends of venous thromboembolism (VTE) in individuals with newly diagnosed primary Sjögren syndrome (pSS) in the general population.Methods.Using a population database that includes all residents of British Columbia, Canada, we created a study cohort of all patients with incident SS and up to 10 controls from the general population matched for age, sex, and entry time. We compared incidence rates (IR) of pulmonary embolism (PE), deep vein thrombosis (DVT), and VTE between the 2 groups according to SS disease duration. We calculated HR, adjusting for confounders.Results.Among 1175 incident pSS cases (mean age 56.7 yrs, 87.6% women), the IR of PE, DVT, and VTE were 3.9, 2.8, and 5.2 per 1000 person-years (PY), respectively; the corresponding rates in the comparison cohort were 0.9, 0.8, and 1.4 per 1000 PY. Compared with non-SS individuals, the multivariable HR for PE, DVT, and VTE among SS cases were 4.07 (95% CI 2.04–8.09), 2.80 (95% CI 1.27–6.17), and 2.92 (95% CI 1.66–5.16), respectively. The HR matched for age, sex, and entry time for VTE, PE, and DVT were highest during the first year after SS diagnosis (8.29, 95% CI 2.57–26.77; 4.72, 95% CI 1.13–19.73; and 7.34, 95% CI 2.80–19.25, respectively).Conclusion.These findings provide population-based evidence that patients with pSS have a substantially increased risk of VTE, especially within the first year after SS diagnosis. Further research into the involvement of monitoring and prevention of VTE in SS may be warranted.


2020 ◽  
Vol 40 (1) ◽  
pp. 8
Author(s):  
Wu-Chien Chien ◽  
Chung-Kan Peng ◽  
Ming-Tsung Chen ◽  
Chung-Kuang Yao ◽  
Chi-Hsiang Chung ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document